跳至主要内容
临床试验/NCT00955513
NCT00955513已完成3 期

A Randomized, Double-blind, Multi-center, Placebo-controlled, 3-treatment Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain

Novartis1 个研究点 分布在 1 个国家目标入组 242 人开始时间: 2009年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Novartis
入组人数
242
试验地点
1
主要终点
Measure: Pain on Movement on Day 5 (Change From Baseline).

研究概览

简要总结

The main purpose of this trial is to compare the efficacy and safety of diclofenac diethylamine 2.32% gel applied twice (b.i.d) or three times a day (t.i.d.) with placebo in the treatment of acute ankle sprains (distortions).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Acute sprain of the lateral ankle, Grade I-II .

排除标准

  • Any concurrent injury affecting the lower extremities that is painful at rest or on movement, or could affect the mobilization of the patient.
  • Topical analgesic or anti-inflammatory treatment over the previous month in the area to be treated.

研究组 & 干预措施

diclofenac diethylamine gel 2.32% gel twice a day

Experimental

drug

干预措施: diclofenac diethylamine gel 2.32% (Drug)

diclofenac diethylamine gel 2.32% gel three times a day

Experimental

drug

干预措施: diclofenac diethylamine gel 2.32% (Drug)

placebo

Placebo Comparator

placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Measure: Pain on Movement on Day 5 (Change From Baseline).

时间窗: baseline and day 5

Visual analog scale (0 to 100 mm) A greater change from baseline equates to a better outcome.

次要结局

未报告次要终点

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验